ZEAL.CO

Zealand Pharma A/S

CPH··DKK

Henter pris…

Værdiansættelse (TTM)

P/Ei

—

EV/EBITDAi

—

P/Bi

—

P/Si

—

EV/Salesi

—

Div yieldi

—

Kursudvikling

Pris

Data-readiness

10 års prishistorik er idealet for høj confidence.

Beregnet 23.6.2026none

Prishistorik: 10,9 år
Pris-dage: 2754
Årsregnskaber: 0
Peers: 0/0
Valuation: 0/6
Fundamentals: 0/8
Datovindue: 2015-05-27 til 2026-06-10

Blokkere

Raw confidence is below the 0.95 high-confidence guardrail.

Mangler før højere confidence

Hent flere årlige SEC-fundamentals for historisk kvalitet.
Kør compute-multiples for manglende valuation metrics.
Kør fetch-fundamentals-bulk/API fallback for manglende regnskabsmetrics.

Seneste assessment

ZEAL.CO vurderet 2026-06-23

Score

21.2%

Ikke high-confidence

Raw confidence is below the 0.95 high-confidence guardrail.

Sell watch placeholder

Stores exit-aware fields without issuing sell scores yet.

Current drawdown: Future exit logic can use drawdown from recent high.

Trend break: Future exit logic can use moving-average trend breaks.

Valuation

Compares price paid with earnings, cash-generation proxies and sales.

50%

P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.

Earnings yield: Earnings yield is the inverse P/E lens.

Technicals

Checks trend, momentum and current damage from recent highs.

6M momentum: Positive medium-term momentum confirms sponsorship.

Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.

Data quality

Checks whether the assessment has enough recent price, fundamental and valuation data.

27%

Price history depth: More than one trading year gives the technical pillar enough context.

Latest price freshness: Latest live or EOD price should be recent.

Macro/regime

Treats macro as context, not a standalone trading instruction.

46%

VIX: Normal volatility is supportive; panic or complacency is less clean.

10Y-2Y curve: Positive yield curve lowers recession stress.

Fundamentals

Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.

50%

Revenue growth 3Y: Sustained top-line growth supports durable compounding.

Gross margin: High gross margin gives room for reinvestment and downturns.

Peer/relative context

Adds relative context when sector peers have comparable data.

50%

Peer count: Peer context is only scored when comparable data exists.

P/E vs peers: P/E relative valuation needs both own multiple and peer median.

Insider activity

Net 90d (aktier)

-1.000

Net 90d (værdi)

-278.000 DKK

Købere 90d

Cluster

—

Dato	Person	Rolle	Type	Antal	Værdi	Kilde
17.6.2026	Nikolaj Frederik Barfoed Beck	Employee elected Board Member	▼ SALG	-1.000	-278.000 DKK	oam
8.6.2026	Anneline Nansen	Board member	◆ OPT.	4.547	412.413 DKK	oam
28.5.2026	Camilla Sylvest	Member of the Board of Directors of Zealand Pharma A/S	· ANDET	4.000	1.291.200 DKK	oam

Earnings

Quarter	Date	EPS actual	EPS est	EPS surprise	Revenue surprise
2026Q1	7.5.2026	-5,58	-9,16	+39.1%	+39.1%	Beat
2025Q4	30.1.2026	-5,19	-8,17	+36.4%	+36.4%	Beat
2025Q3	30.10.2025	-5,75	-10,42	+44.8%	+44.8%	Beat
2025Q2	30.7.2025	105,61	109,53	-3.6%	-3.6%	Inline